Treatment with nilotinib after cytogenetic relapse at 12 months in a patient in chronic phase with sub-optimal response to imatinib
We report a case of patient with chronic myeloid leukemia who started imatinib at standard dose and obtained a sub-optimal response at 6 months. Considering the patient as a possible “late responder”, we decided not to change the imatinib dose, but, at 12 months, we did not achieve a complete cytoge...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd
2015-10-01
|
| Series: | Clinical Management Issues |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1092 |